We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
LAVA (LVTX) Up on J&J's (JNJ) Cancer Study Candidate Selection
Read MoreHide Full Article
LAVA Therapeutics’ (LVTX - Free Report) shares were up almost 27% on Jun 1, after market hours. This followed soon after Janssen Biotech, a subsidiary of Johnson & Johnson (JNJ - Free Report) , announced that it selected a lead candidate for further development in clinical studies for cancer.
The decision was made as part of a collaboration agreement between the two companies (signed in May 2020). The study aims to discover and create bispecific antibodies that target gamma-delta T cells as a potential cancer treatment.
Per the terms of the aforementioned agreement, Janssen will be responsible for the future clinical development, manufacturing and commercialization of the selected candidate at its own expense.
LVTX has the opportunity to earn potential milestone payments as well as royalties based on sales of developed products.
LAVA’s shares have plunged 45.7% year to date compared with the industry’s 9.4% decline.
Image Source: Zacks Investment Research
LVTX is focused on developing its novel Gammabody platform that generates bispecific gamma-delta T cell engagers to target cancer cells and trigger an immune response in patients.
The company is developing its lead candidate, LAVA -051, in a phase I/IIa dose escalation study targeting multiple myeloma, chronic lymphocytic leukemia and acute myeloid leukemia.
LAVA has further expanded its portfolio of potential cancer therapy by entering into a license agreement with Seagen in September 2022. The agreement was aimed at the development of SGN-EGFRd2 (LAVA-1223) for treating solid tumors.
LVTX received an upfront payment of $50 million on the deal and could receive up to approximately $650 million in potential development, regulatory and commercial milestones from Seagen.
Loss per estimates for ADMA have narrowed from 14 cents to 9 cents for 2023 in the past 60 days. Shares of ADMA have risen 3.4% in the year-to-date period.
ADMA Biologics’ earnings beat estimates in three of the trailing four quarters and met the mark in one, delivering an average surprise of 19.3%.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
LAVA (LVTX) Up on J&J's (JNJ) Cancer Study Candidate Selection
LAVA Therapeutics’ (LVTX - Free Report) shares were up almost 27% on Jun 1, after market hours. This followed soon after Janssen Biotech, a subsidiary of Johnson & Johnson (JNJ - Free Report) , announced that it selected a lead candidate for further development in clinical studies for cancer.
The decision was made as part of a collaboration agreement between the two companies (signed in May 2020). The study aims to discover and create bispecific antibodies that target gamma-delta T cells as a potential cancer treatment.
Per the terms of the aforementioned agreement, Janssen will be responsible for the future clinical development, manufacturing and commercialization of the selected candidate at its own expense.
LVTX has the opportunity to earn potential milestone payments as well as royalties based on sales of developed products.
LAVA’s shares have plunged 45.7% year to date compared with the industry’s 9.4% decline.
Image Source: Zacks Investment Research
LVTX is focused on developing its novel Gammabody platform that generates bispecific gamma-delta T cell engagers to target cancer cells and trigger an immune response in patients.
The company is developing its lead candidate, LAVA -051, in a phase I/IIa dose escalation study targeting multiple myeloma, chronic lymphocytic leukemia and acute myeloid leukemia.
LAVA has further expanded its portfolio of potential cancer therapy by entering into a license agreement with Seagen in September 2022. The agreement was aimed at the development of SGN-EGFRd2 (LAVA-1223) for treating solid tumors.
LVTX received an upfront payment of $50 million on the deal and could receive up to approximately $650 million in potential development, regulatory and commercial milestones from Seagen.
LAVA Therapeutics N.V. Price and Consensus
LAVA Therapeutics N.V. price-consensus-chart | LAVA Therapeutics N.V. Quote
Zacks Rank and Stock to Consider
Currently, LAVA carries a Zacks Rank #3 (Hold).
A better-ranked stock in the same sector is ADMA Biologics (ADMA - Free Report) , carrying a Zacks Rank #2 (Buy) at present. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Loss per estimates for ADMA have narrowed from 14 cents to 9 cents for 2023 in the past 60 days. Shares of ADMA have risen 3.4% in the year-to-date period.
ADMA Biologics’ earnings beat estimates in three of the trailing four quarters and met the mark in one, delivering an average surprise of 19.3%.